<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30053900</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>01</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1465-542X</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>20</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Jul</Month>                        <Day>27</Day>                    </PubDate>                </JournalIssue>                <Title>Breast cancer research : BCR</Title>                <ISOAbbreviation>Breast Cancer Res.</ISOAbbreviation>            </Journal>            <ArticleTitle>The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>79</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13058-018-1012-0</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The PAM50-based (Prosigna) risk of recurrence (ROR) score and intrinsic subtypes are prognostic for women with high-risk breast cancer. We investigate the predictive ability of Prosigna regarding the effectiveness of cyclophosphamide-based adjuvant chemotherapy in premenopausal patients with high-risk breast cancer.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Prosigna assays were performed on the NanoString platform in tumors from participants in Danish Breast Cancer Group (DBCG) 77B, a four-arm trial that randomized premenopausal women with high-risk early breast cancer to no systemic treatment, levamisole, oral cyclophosphamide (C) or cyclophosphamide, methotrexate and fluorouracil (CMF).</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, this retrospective analysis included 460 women (40% of the 1146 randomized patients). The continuous Prosigna ROR score was prognostic in the no systemic treatment group (unadjusted P &lt; 0.001 for disease-free survival (DFS), P = 0.001 for overall survival (OS)). No statistically significant interaction of continuous ROR score and treatment on DFS and OS was found. A highly significant association was observed between intrinsic subtypes and C/CMF treatment for DFS (P<sub>interaction</sub> = 0.003 unadjusted, P = 0.001 adjusted) and OS (P<sub>interaction</sub> = 0.04). In the adjusted analysis treatment with C/CMF was associated with a reduced risk of DFS events in patients with basal-like (hazard ratio (HR) 0.14; 95% CI 0.06; 0.32) and luminal B (HR 0.48; 95% CI 0.27; 0.84) subtypes but not in patients with Human epidermal growth factor receptor-enriched (HR 1.05; 95% CI 0.56; 1.95) or luminal A (HR 0.61; 95% CI 0.32; 1.16) subtypes.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The Prosigna ROR score and intrinsic subtypes were prognostic in high-risk premenopausal patients with breast cancer, and intrinsic subtypes identify high-risk patients with or without major benefit from adjuvant C/CMF treatment.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Jensen</LastName>                    <ForeName>Maj-Britt</ForeName>                    <Initials>MB</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5348-3040</Identifier>                    <AffiliationInfo>                        <Affiliation>Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen University Hospital, DBCG Secretariat, Bldg. 2501 Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen, Denmark. mj@dbcg.dk.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lænkholm</LastName>                    <ForeName>Anne-Vibeke</ForeName>                    <Initials>AV</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Pathology, Zealand University Hospital, Slagelse, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nielsen</LastName>                    <ForeName>Torsten O</ForeName>                    <Initials>TO</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Eriksen</LastName>                    <ForeName>Jens Ole</ForeName>                    <Initials>JO</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Pathology, Zealand University Hospital, Slagelse, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wehn</LastName>                    <ForeName>Pernille</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgical Pathology, Zealand University Hospital, Slagelse, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hood</LastName>                    <ForeName>Tressa</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>NanoString Technologies, Inc, Seattle, WA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ram</LastName>                    <ForeName>Namratha</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>NanoString Technologies, Inc, Seattle, WA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Buckingham</LastName>                    <ForeName>Wesley</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>NanoString Technologies, Inc, Seattle, WA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ferree</LastName>                    <ForeName>Sean</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>NanoString Technologies, Inc, Seattle, WA, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ejlertsen</LastName>                    <ForeName>Bent</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Danish Breast Cancer Cooperative Group, Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>27</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Breast Cancer Res</MedlineTA>            <NlmUniqueID>100927353</NlmUniqueID>            <ISSNLinking>1465-5411</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2014 Mar 13;14:177</RefSource>                <PMID Version="1">24625003</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2010 May 1;116(9):2081-9</RefSource>                <PMID Version="1">20186830</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2005 Oct 20;23(30):7483-90</RefSource>                <PMID Version="1">16234514</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2007 Mar;43(5):877-84</RefSource>                <PMID Version="1">17306974</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2012 Feb 4;379(9814):432-44</RefSource>                <PMID Version="1">22152853</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS Med. 2012;9(5):e1001216</RefSource>                <PMID Version="1">22675273</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2017 Aug 10;35(23):2647-2655</RefSource>                <PMID Version="1">28398846</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2000 Aug 17;406(6797):747-52</RefSource>                <PMID Version="1">10963602</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2017 Feb 15;23(4):946-953</RefSource>                <PMID Version="1">27601592</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2014 Feb;25(2):339-45</RefSource>                <PMID Version="1">24347518</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2012 Apr 15;18(8):2402-12</RefSource>                <PMID Version="1">22351696</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Acta Oncol. 2014 Jun;53(6):776-87</RefSource>                <PMID Version="1">24359601</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2010 Nov 1;16(21):5222-32</RefSource>                <PMID Version="1">20837693</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2016 Jun;27(6):1035-40</RefSource>                <PMID Version="1">27022068</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2011 Nov;12(12):1134-42</RefSource>                <PMID Version="1">21917518</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Med Genomics. 2015 Aug 22;8:54</RefSource>                <PMID Version="1">26297356</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Treat Res. 1992;60:371-4</RefSource>                <PMID Version="1">1355998</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2017 Aug 10;35(23):2639-2646</RefSource>                <PMID Version="1">28661759</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 1976 Feb 19;294(8):405-10</RefSource>                <PMID Version="1">1246307</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2009 May 6;101(9):644-50</RefSource>                <PMID Version="1">19401546</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2010 Jan;11(1):55-65</RefSource>                <PMID Version="1">20005174</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2005 May 14-20;365(9472):1687-717</RefSource>                <PMID Version="1">15894097</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Adjuvant chemotherapy</Keyword>            <Keyword MajorTopicYN="N">Breast neoplasms</Keyword>            <Keyword MajorTopicYN="N">CMF</Keyword>            <Keyword MajorTopicYN="N">Cyclophosphamide</Keyword>            <Keyword MajorTopicYN="N">PAM50</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>03</Month>                <Day>19</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>02</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>7</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30053900</ArticleId>            <ArticleId IdType="doi">10.1186/s13058-018-1012-0</ArticleId>            <ArticleId IdType="pii">10.1186/s13058-018-1012-0</ArticleId>            <ArticleId IdType="pmc">PMC6062869</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>